Key result
Finerenone targets mineralocorticoid receptor hyperactivation to improve cardiorenal outcomes in diabetes.
Why the study?
Does finerenone prevent cardiorenal complications in patients with diabetes mellitus?
Does finerenone prevent cardiorenal complications in patients with diabetes mellitus?
Finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, offers a promising therapeutic approach to mitigate MCR hyperactivation-driven cardiorenal complications in patients with diabetes mellitus.
The renin-angiotensin-aldosterone system (RAAS) activation plays a key role in the chronic kidney disease (CKD) progression and in the cardiovascular complications (CVC) development in patients with diabetes mellitus (DM). RAAS blockers alone are not sufficient to prevent CVC and CVC progression. RAAS upregulation in CKD associated with DM triggers the mineralocorticoid receptors (MCR) hyperactivation which results in fibrosis and inflammation in the heart and kidneys. This review presents the current data about the variety of MCR hyperactivation manifestations, as well as about of multiplicity of MCR hyperactivation ways in DM. The efficacy and safety of finerenone, a new MCR nonsteroidal selective antagonist, are discussed.
No takes yet. Share an insight, caveat, or question.
Irina Nikolaevna Bobkova (2023) conducted a review in Diabetes mellitus and chronic kidney disease. Finerenone was evaluated. This review discusses the role of mineralocorticoid receptor hyperactivation in cardiorenal complications in diabetes mellitus and the efficacy and safety of finerenone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: